January 11, 2012 8:23 PM | 2 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Below are highlights from Benzinga's daily coverage of microcap securities making big moves:
Pressure BioSciencesShares of Pressure BioSciences (NASDAQ: PBIO), the South Easton, MA life sciences company, rose 44% Wednesday on 9 times the average daily volume.Pressure BioSciences and Digilab announced Wednesday that they have entered into a co-marketing/selling and research and development agreement. The companies intend to co-market and sell their respective product lines worldwide, including in industry publications, at scientific meetings, on each company's website, through common collaborator studies, at key industry trade shows, and in visits to customer sites. PBI and Digilab also intend to explore ways to co-develop new instrumentation, accessories/modules for existing instrumentation, and consumables that combine the robotics and high throughput capabilities of Digilab products with the extraction, protein digestion, and other advantages of PBI's Pressure Cycling Technology Platform.Pressure BioSciences shares traded Wednesday in a range of $0.57 to $0.82 and closed at $0.78.
Hemispherx BiopharmaShares of Hemispherx Biopharma (NYSE: HEB), the Philadelphia, PA specialty pharmaceutical company, rose 14% Wednesday on 3.3 times the average daily volume.Hemispherx announced Wednesday that the Food and Drug Administration granted an extension for the company to modify its New Drug Application in response to a Complete Response Letter received November 25, 2009 for the Chronic Fatigue Syndrome therapeutic indication. The extension will remain open while Hemispherx submits an amended NDA.In the request for extension, the company advised the FDA of the findings presented at the IACFS/ME Biennial Scientific Conference held September 22-25, 2011 in Ottawa, Ontario, Canada of a new potential companion diagnostic tests for CFS.Hemispherx Biopharma shares traded Wednesday in a range of $0.22 to $0.25, closing at $0.24.
SpherixShares of Spherix (NASDAQ: SPEX), the Bethesda, MD pharmaceutical company, rose 17% Wednesday on 21 times the average daily volume.Spherix reported Wednesday, the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106. Results demonstrated an ample margin of safety with the dosing planned for the first-in-human study. The toxicology report will be included in the Investigational New Drug submission to the U.S. Food and Drug Administration, which is expected to be submitted in the second quarter of 2012.Spherix shares traded Wednesday in a range of $1.20 to $1.77, closing at $1.40.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.